linjc16/ctgov huggingface dataset:
Women With Minor Degrees of Glucose Intolerance and the Postpartum Glucose Tolerance Test

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to offer a 75g postpartum glucose tolerance test to women with minor degrees of glucose intolerance and to assess if these women are significantly different from women who were diagnosed as GDM (Gestational Diabetes Mellitus)

Official Title
-----------------
Women With Minor Degrees of Glucose Intolerance and the Postpartum Glucose

Conditions
-----------------
Glucose Tolerance Impaired in Pregnancy

Intervention / Treatment
-----------------
* Diagnostic Test: 75g oral glucose tolerance test
* Diagnostic Test: 75g GTT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy women (without pre-existing diabetes) who underwent an OGTT during pregnancy Exclusion Criteria: pre-existing diabetes, or failed to perform the OGTT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: One abnormal value<br>Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy | Diagnostic Test: 75g oral glucose tolerance test<br>* Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM<br>|
| Active Comparator: GDM<br>Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM | Diagnostic Test: 75g GTT<br>* post-partum GTT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive post-partum GTT results |  | 6-12 weeks post partum |
Splinting for Dupuytren's Contracture Release

Study Overview
=================
Brief Summary
-----------------
This study is comparing two different kinds of splints for patients who have had a surgical contracture release of dupuytren's disease. It compares a static splint and a dynamic splint.

Official Title
-----------------
Prospective Randomized Comparison of Dynamic Versus Static Splinting After Dupuytren's Contracture Release

Conditions
-----------------
Dupuytren's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older males and females with Dupuytren's contracture patients with contracture of less than 30 degrees of MCP contractions and no contractions of the IP joints Exclusion Criteria: previous surgical treatment for Dupuytren's contracture of MCP greater than 30 degrees contraindications for dynamic splinting (upper limb amputees, paresis, ect.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Static Splint | |
| 2<br>Dynamic Splint | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DASH questionnaire, PCS questionnaire, Wahler Physical Symptom Inventory, CESD questionnaire |  | 6 months |
An Intervention to Decrease Infant Crying

Study Overview
=================
Brief Summary
-----------------
This is a study looking at the Happiest Baby on the Block technique. The investigators hypothesized that infants of mothers given a 30 minute videotape demonstrating the Happiest Baby on the Block technique would fuss/cry less and sleep longer than infants of mothers given a 30 minute videotape on general newborn care. The investigators also hypothesized that mothers given the Happiest Baby on the Block videotape would have lower levels of stress.

Detailed Description
-----------------
Mothers recorded their babies fussing, crying and sleeping on paper diaries when their infants were 1, 4, 6, 8 and 12 weeks old.

Official Title
-----------------
A Randomized, Controlled Trial to Decrease Infant Crying

Conditions
-----------------
Colic

Intervention / Treatment
-----------------
* Behavioral: Happiest Baby videotape
* Behavioral: control videotape


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mothers of singleton newborns 37 to 41 week gestation healthy (no ICU admission) Exclusion Criteria: not able to view videotape at home not able to speak English

Ages Eligible for Study
-----------------
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Happiest Baby videotape<br>videotape describing the Happiest Baby on the Block technique | Behavioral: Happiest Baby videotape<br>* a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants<br>* Other names: Happiest Baby on the Block technique;|
| Placebo Comparator: control videotape<br>videotape with normal newborn instruction | Behavioral: control videotape<br>* a videotape with general newborn care instructions<br>* Other names: Civitas' Begin with Love;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hours Per Day of Fuss/Cry | total hours per day of fuss, cry, and unsoothable crying. | week 8 | 
| Hours Per Day of Sleep | mean sleep time is the mean of 3 daily sleep times reported in a time period. | week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parenting Stress Index | a continuous scale measuring stress with a range of 131 (low) to 320 (high); the average person's stress scores are between 188 and 252. | week 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colic, crying, clinical trial
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

Study Overview
=================
Brief Summary
-----------------
The study will be double blind with respect to rifaximin, and randomization will be performed using tables of computer-generated random numbers. All subjects will be followed up till the recovery of HE (primary end point) or 10 days whichever is earlier. In the Lactulose group (group A) patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day along with placebo . In the lactulose plus rifaximin group (group B) patients will receive cap rifaximin 400mg three times a day along with lactulose. Primary endpoints will be recovery of overt HE patients who will not recover from HE after 10 days will be continued on the same treatment. Total duration of the study is 1 year.

Official Title
-----------------
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

Conditions
-----------------
Hepatic Encephalopathy

Intervention / Treatment
-----------------
* Drug: Rifaximin plus lactulose
* Drug: Lactulose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cirrhosis Age 18-80 Hepatic encephalopathy grade II-IV Informed consent Exclusion Criteria: Degenerative CNS disease or major psychiatric illness Serum creatinine > 1.5 mg/dl Active alcohol intake <4 weeks prior to present episode Others metabolic encephalopathies Hepatocellular Carcinoma Severe comorbidity such as CHF, Pulmonary disease, Neurological & Psychiatric problems impairing quality of life

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rifaximin plus lactulose<br> | Drug: Rifaximin plus lactulose<br>* Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.<br>|
| Active Comparator: lactulose<br>30-60ml/day | Drug: Lactulose<br>* Lactulose 30-60 ml in two or three divided doses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reversal of hepatic encephalopathy |  | 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death |  | 10 days | 
| duration of hospital stay |  | 10 days |
Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
The Acute Respiratory Distress Syndrome (ARDS) is one of common clinical critically diseases. In the United States, the incidence of ARDS reaches 31%, which is one of the main causes of death in patients. There is no unified treatment process for ARDS currently and the treatment measures are not yet standardized, so the standardization of ARDS treatment processes is needed to reduce mortality in patients. Following the evidence-based medicine principles and six-step treatment standards of ARDS, this study uses the method of multi-center randomized controlled clinical trials to evaluate the standardized treatment process of ARDS, which provides the basis for the standardized treatment of ARDS.

Official Title
-----------------
Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome

Conditions
-----------------
Respiratory Failure, Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged ≥ 18 years admitted to the ICU according to the diagnostic criteria of ARDS Berlin definition，admit patients with severe ARDS Exclusion Criteria: age <18 years old be expected to die within 24 hours end-stage malignancies be participating in other studies, which may affect the results of this study DNI (do not intubation) and DNR (do not recovery) patients family members do not agree to sign an informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| standard treatments of ARDS<br> | |
| protocol treatment of ARDS<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of medical staff who comply the protocol treatment |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mechanical ventilation, ARDS, Ventilator strategy, outcome
Comparative Study of the Protein C Pathway in Septic and Non Septic Patients With Organ Failure

Study Overview
=================
Brief Summary
-----------------
This is a comparative study performed in 3 groups of patients/subjects: 30 severe sepsis patients, 30 non-septic patients with organ failure, 30 healthy subjects. The only intervention is a venous blood sampling at the onset of the disease. The purpose of the study is to compare the PC pathway and expression and inflammatory genes between the 3 groups. The main hypothesis is that systemic inflammatory response and exacerbated coagulation activation are non specific of an infection as a triggering event.

Detailed Description
-----------------
analysis of the PC pathway PC activity PS activity soluble thrombomodulin soluble EPCR activated protein C quantitative flow cytometry on monocytes (thrombomodulin and EPCR) whole blood mRNA (Tissue factor, thrombomodulin and EPCR) inflammatory gene expression analysis by MLPA

Official Title
-----------------
Comparative Study of the Protein C Pathway in Septic and Non Septic Patients

Conditions
-----------------
Severe Sepsis, Organ Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe sepsis patients or: non-septic acute organ failure patients or: healthy subjects matched for age and sex with severe sepsis patients Exclusion Criteria: criteria for organ failure lasting for more than 24 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
severe sepsis, organ failure, activated protein C, thrombomodulin, EPCR
Optimal Initiation of Helicobacter Pylori Eradication After Endoscopic Resection for Gastric Neoplasm

Study Overview
=================
Brief Summary
-----------------
After endoscopic resection (ER) of gastric tumors, eradication of Helicobacter pylori (H. pylori) infection is advised to reduce metachronous recurrence. However, few studies have addressed factors influencing H. pylori eradication rates in the aftermath of ER, and none have focused on the optimal timing of therapy to eradicate H. pylori post-ER.Therefore, the investigators will conduct to evaluate whether differences in timing of eradication therapy after ER of gastric tumors.

Official Title
-----------------
Optimal Initiation of Helicobacter Pylori Eradication After Endoscopic Resection

Conditions
-----------------
H.Pylori Eradication Rate

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients underwent endoscopic resection of gastric neoplasm patients who diagnosed as H. pylori infection by rapid urease test Exclusion Criteria: Histories of gastric surgery Histories of prior H. pylori eradication therapy Use of drugs affecting H. pylori positivity (proton pump inhibitor, histamine-2 receptor blocker, or antibiotics) within the preceding 2 weeks

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| early eradication group<br>In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks). | |
| late eradication group<br>In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| H. pylori eradication rate according to timing of therapeutic regimen after endoscopic resection |  | 4 weeks after completion of H.pylori eradiation therapy |
Ultrasound in Airway Assessment of Morbidly Obese Patients

Study Overview
=================
Brief Summary
-----------------
the study aims to evaluate the role of airway ultrasound as a new evolving modality in assessment and management of airway in surgical patients

Conditions
-----------------
General Anesthesia of Morbid Obese Patients

Intervention / Treatment
-----------------
* Device: airway ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all surgical list patients planned for general anesthesia from october 2015 to may 2016 Exclusion Criteria: Patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: airway ultrasound|airway assessment using ultrasound|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prediction of difficult intubation in morbid obese patients | prediction of difficult intubation in morbid obese versus traditional airway scores; Mallampati score. | during endotracheal tube insertion |
Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduction.

Study Overview
=================
Brief Summary
-----------------
Women in assisted reproduction treatment they receive own or donated embryos and presenting an endometrial development less than 5 mm despite having received treatment with estrogen therapy knowing the clinical value of using the PRGF-Endoret therapy and endometrial level applications to improve endometrial thickness endometrial preparations for embryo transfer.

Official Title
-----------------
Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity

Conditions
-----------------
Endometrial Development

Intervention / Treatment
-----------------
* Drug: Growth Factor, Platelet-Derived


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. Less than 5mm despite 10 days with standard doses of estrogen therapy (6mg / 24h) Endometrio Exclusion Criteria: History of pelvic inflammatory disease Risk of infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endometrium with less than 5mm<br>Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. Less than 5mm despite 10 days with standard doses of estrogen | Drug: Growth Factor, Platelet-Derived<br>* 0,5 mL, vaginal use , 3 dose number<br>|
| No Intervention: Endometrium with more than 5mm<br>Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. More than 5mm despite 10 days with standard doses of estrogen | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the growth of endometrial thickness | The endometrial thickness will be measured by vaginal ultrasound. Endometrium less than 5 mm will be treated | During ovarian stimulation protocol 8-12 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyze the impact of using platelet plasma on rates of implantation and pregnancy. | The biochemical determination of the hormone ßhcg will be performed 12 days after embryo transfer | During ovarian stimulation protocol 8-12 days |
Prediction of Postoperative Pain by an Electrical Pain Stimulus

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate a possible correlation between predictive precesarean section pain and development of postcaesarean section pain using the PM. Patients and Methods 46 healthy pregnant women scheduled for elective cesarean section is included after informed consent. The standard operation procedures included spinal anesthesia, paracetamol 1 g 8 hourly, diclofenac 50 mg 8 hourly and oxycontine 10 mg x 2. Morphine was used for break-through pain. Before cesarian section the threshold for sensory and pain were measured 3 times, and the average was used for analyses. After cesarian section a blinded midwife assess the pain at rest and during mobilization every 12th hours over 2 days score. Data was analyzed using AUC and non-parametric test, P < 0,05.

Conditions
-----------------
Cesarean Section

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy pregnant women scheduled for elective cesarean section Exclusion Criteria: ASA III -IV Chronic pain conditions. Pacemaker.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |